研究者情報

トミタ　ハヤト   TOMITA HAYATO   冨田隼人    所属   医学部医学科 放射線診断・ＩＶＲ学    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Predictive Value of VIBE using Subtraction to Evaluate Idiopathic Facial Palsy after Starting Therapy
掲載誌名	正式名：Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 略　 称：Rofo
掲載区分	国外
巻・号・頁	doi: 10.1055/a-1160-6047.頁
著者・共著者	Hayato Tomita, Klaus Detmar, Panagiota Manava, Yasuo Nakajima, Michael Lell, Ralf Adamus
担当区分	筆頭著者,責任著者
発行年月	2020/06
概要	Purpose: To determine the predictive value of 3-dimensional spoiled gradient-echo volumetric interpolated breath-hold examination (VIBE) using subtraction to evaluate the short-term effect of therapy for facial palsy. Materials and methods: We included 97 patients with idiopathic facial palsy (52 male, 45 female; aged 50.7 ± 19.4 years) who underwent MR imaging with a contrast agent after starting therapy. The mean interval between onset and therapy was 1.55 ± 1.69 days, between therapy and MR imaging was 3.19 ± 2.78 days, and between MR imaging and assessment of the therapeutic effect was 3.50 ± 0.71 days. The degree of therapeutic effect was determined using a 4-grade scale based on the House-Brackmann scale for grading facial nerve function. Two radiologists reviewed VIBE with pre- and postcontrast subtraction using the 4-point scale. We evaluated the diagnostic performance and compared the degree of therapeutic effect and enhancement of facial nerves that were divided into 5 segments bilaterally. Results: We identified 98 facial palsy initially and significant enhancement in 55 facial nerves after the start of therapy and residual palsy in 87. Sensitivity for all facial palsy was 62.0 %, specificity was 90.9 %, positive predictive value was 98.2 %, negative predictive value was 23.3 %, and accuracy was 65.3 %. Eleven patients recovered completely, 1 showed significant enhancement, and the remaining 10 did not show significant enhancement of the facial nerve. Conclusion: VIBE has a potential to predict the prognostic outcome and assess facial palsy after the start of therapy.